Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
News|Articles|April 10, 2026
The Hidden Risks of Performance Enhancement: Pharmacists Are Critical to Protecting Athletes in a “Quick-Fix” Era
Author(s)Danielle Valletti, Assistant Editor
Advertisement
Advertisement
At the 2026 Sports Pharmacy Summit in Fort Lauderdale, Travis Tygart, CEO of the United States Anti-Doping Agency (USADA), delivered a keynote that reframed the modern doping conversation—not as an isolated issue of elite misconduct, but as a growing public health concern shaped by accessibility, misinformation, and cultural pressure.1
Related to this article
Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Advertisement
Advertisement